All In Biotech

Drug Trial Radar · NCT03345342

A Study of Paliperidone Palmitate 6-Month Formulation

A Double-blind, Randomized, Active-controlled, Parallel-group Study of Paliperidone Palmitate 6-Month Formulation

Last checked: Nov 19, 2026Latest source record: Apr 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 841 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

841

Actual

Start

Nov 20, 2017

Primary completion

May 8, 2020

Study completion May 8, 2020

Sponsor

Lead sponsor
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Nov 17, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to demonstrate that injection cycles consisting of a single administration of paliperidone palmitate 6-month (PP6M) are not less effective than 2 sequentially administered injections of paliperidone palmitate 3-month PP3M) (350 or 525 mg eq.) for the prevention of relapse in participants with schizophrenia previously stabilized on corresponding doses of paliperidone palmitate 1-month (PP1M) (100 or 150 mg eq.) or PP3M (350 or 525 mg eq.).

Conditions

  • Schizophrenia

Interventions

  • PP6MDrug

    Participants will receive intramuscular injection of PP6M.

  • PP3M 350 mg eq.Drug

    Participants will receive intramuscular injection of PP3M 350 mg eq.

  • PP3M 525 mg eq.Drug

    Participants will receive intramuscular injection of PP3M 525 mg eq.

  • PP1MDrug

    Participants will receive intramuscular injection of PP1M 50 to 150 mg eq.

  • PlaceboOther

    Participants will receive matching placebo.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to Relapse During the Double-Blind (DB) PhaseTime frame: Up to 12 months of DB Phase

Locations

138 sites in 21 countries. Site status is shown where the registry gives one.

  • Woodland Research Northwest

    Rogers, Arkansas

  • California Pharmaceutical Research Institute, Inc.

    Anaheim, California

  • ATP Clinical Research

    Costa Mesa, California

  • Collaborative NeuroScience Network

    Garden Grove, California

  • Synergy East

    Lemon Grove, California

  • Pacific Research Partners

    Oakland, California

  • SF-Care, Inc

    San Rafael, California

  • New Life Medical Research Center, Inc.

    Hialeah, Florida

  • Clintex Research Group

    Miami, Florida

  • Florida Research Center Inc.

    Miami, Florida

  • Olympian Clinical Research

    Tampa, Florida

  • Atlanta Center for Medical Research

    Atlanta, Georgia

  • Uptown Research Institute

    Chicago, Illinois

  • Alexian Behavioral Health Hospital

    Hoffman Estates, Illinois

  • Ascension via Christi Research

    Wichita, Kansas

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Cherry Street Services, Inc.

    Grand Rapids, Michigan

  • St. Louis Clinical Trials

    St Louis, Missouri

  • The Zucker Hillside Hospital

    Glen Oaks, New York

  • Clinical Trials of America Inc

    Hickory, North Carolina

  • Wexner Medical Center at the Ohio State University

    Columbus, Ohio

  • Midwest Clinical Research Center

    Dayton, Ohio

  • University of Pennsylvania Medical Center

    Philadelphia, Pennsylvania

  • Future Search Trials of Dallas

    Dallas, Texas

  • Psychiatric and Behavioral Solutions

    Salt Lake City, Utah

  • Fundacion para el Estudio y Tratamiento de las Enfermedades Mentales

    Buenos Aires, Argentina

  • CEN

    Córdoba, Argentina

  • Sanatorio Prof. Leon S. Morra

    Córdoba, Argentina

  • Instituto de Neurociencias San Agustin

    La Plata, Argentina

  • Clinica Privada de Salud Mental Santa Teresa de Ávila

    La Plata, Argentina

  • C I A P Centro de investigacion y Asistencia en Psiquiatria

    Rosario, Argentina

  • The Lyell McEwin Hospital

    Elizabeth Vale, Australia

  • Neuro Trials Victoria

    Noble Park, Australia

  • Trial Tech Tecnologia em Pesquisas com Medicamentos

    Curitiba, Brazil

  • Instituto Bairral de Psiquiatria

    Itapira, Brazil

  • Hospital das Clinicas de Porto Alegre

    Porto Alegre, Brazil

  • Ruschel Medicina e Pesquisa Clínica Ltda

    Rio de Janeiro, Brazil

  • CPQuali Pesquisa Clinica LTDA ME

    São Paulo, Brazil

  • SPDM - Associacao Paulista para o Desenvolvimento da Medicina - Hospital Sao Paulo

    São Paulo, Brazil

  • Hospital Das Clinicas Da Faculdade De Medicina Da USP

    São Paulo, Brazil

Showing 40 of 138 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.